JP2025510490A - 抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン - Google Patents

抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン Download PDF

Info

Publication number
JP2025510490A
JP2025510490A JP2024547780A JP2024547780A JP2025510490A JP 2025510490 A JP2025510490 A JP 2025510490A JP 2024547780 A JP2024547780 A JP 2024547780A JP 2024547780 A JP2024547780 A JP 2024547780A JP 2025510490 A JP2025510490 A JP 2025510490A
Authority
JP
Japan
Prior art keywords
antibody
subject
ivig
dose
clovalimab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510490A5 (https=
JPWO2023194271A5 (https=
Inventor
ブアトワ，シモン・ベルトラン・マリー
圭介 五反田
賢治 四宮
ソステリー，アレクサンドル・アントワーヌ・ベルナール
ソウブレト，アントワーヌ・パウル・マクセンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2025510490A publication Critical patent/JP2025510490A/ja
Publication of JP2025510490A5 publication Critical patent/JP2025510490A5/ja
Publication of JPWO2023194271A5 publication Critical patent/JPWO2023194271A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024547780A 2022-04-04 2023-04-03 抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン Pending JP2025510490A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166586 2022-04-04
EP22166586.2 2022-04-04
PCT/EP2023/058605 WO2023194271A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (3)

Publication Number Publication Date
JP2025510490A true JP2025510490A (ja) 2025-04-15
JP2025510490A5 JP2025510490A5 (https=) 2026-04-03
JPWO2023194271A5 JPWO2023194271A5 (https=) 2026-04-03

Family

ID=81327980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547780A Pending JP2025510490A (ja) 2022-04-04 2023-04-03 抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン

Country Status (11)

Country Link
US (1) US20250236661A1 (https=)
EP (1) EP4504773A1 (https=)
JP (1) JP2025510490A (https=)
KR (1) KR20240168923A (https=)
CN (1) CN118556078A (https=)
AU (1) AU2023248634A1 (https=)
CA (1) CA3251879A1 (https=)
IL (1) IL313962A (https=)
MX (1) MX2024009673A (https=)
TW (1) TW202346339A (https=)
WO (1) WO2023194271A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
US20230303670A1 (en) * 2020-06-24 2023-09-28 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions

Also Published As

Publication number Publication date
MX2024009673A (es) 2024-09-11
AU2023248634A1 (en) 2024-05-16
CA3251879A1 (en) 2023-10-12
US20250236661A1 (en) 2025-07-24
EP4504773A1 (en) 2025-02-12
IL313962A (en) 2024-08-01
TW202346339A (zh) 2023-12-01
KR20240168923A (ko) 2024-12-02
WO2023194271A1 (en) 2023-10-12
CN118556078A (zh) 2024-08-27

Similar Documents

Publication Publication Date Title
KR20220044563A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
WO2019186369A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
WO2022090169A1 (en) Method of safe administration of anti-tau antibody
KR20250107839A (ko) 심혈관계 질환의 치료 방법
US20220356261A1 (en) Treatment for sjögren's syndrome
JP2025510490A (ja) 抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
JP2025511382A (ja) 抗ｃ５抗体クロバリマブの使用によるギラン－バレー症候群の処置または予防のための投与量および投与レジメン
TW202337913A (zh) 每週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
CN109641053A (zh) 给药方案
KR102628314B1 (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
WO2025096435A1 (en) Treatment of complement-associated renal diseases
JP2025133872A (ja) Ｆｖｉｉｉ模倣二重特異性抗体を２ヶ月に１回投与する方法
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
TW202345897A (zh) 每月投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
TW202345896A (zh) 每兩週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260325